Page 11 of 32 · 745 questions tagged clinical-trials.
The case in front of me: SURMOUNT-2 · fatigue. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single…
Concretely: early satiety · tirzepatide · SURMOUNT-2. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if…
I am asking about the protocol logic rather than about my own case specifically. I want to understand what this actually establishes, as opposed to what it is being…
What I have: injection-site erythema · oral semaglutide · PIONEER-4. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not…
Setup, so nobody has to ask: STEP 2 · dizziness. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
The particulars: SUSTAIN-6 · semaglutide. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am…
The specifics, since they change the answer: TRIUMPH-1 · retatrutide. Somebody stated this to me confidently and I would like to check it before repeating it. I would…
What I am working with: FLOW · injection-site erythema · 1 mg. I have read the primary source rather than the summary, which has left me with more questions. I…
The specifics, since they change the answer: PIONEER-4 · headache · 14 mg. I have the document in front of me and I can read the numbers. What I cannot do is…
The particulars: FLOW · semaglutide. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am being…
The case in front of me: oral semaglutide · mazdutide. I am trying to choose between two options that are usually discussed as though only one exists. I am not…
Conditions: STEP 4 · fatigue · 1 mg. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics…
What I have: SURMOUNT-5 · 15 mg. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree, which…
Every trial in metabolic dysfunction-associated steatohepatitis reports two co-primary endpoints with oddly constructed names: "resolution of steatohepatitis without…
The case in front of me: ecnoglutide · 37 °C. I want to know whether there is evidence behind this or only repetition. I have checked the obvious registries and…
The particulars: TRIUMPH-3 · 4 mg. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am being…
I am asking about the protocol logic rather than about my own case specifically. I want to understand what this actually establishes, as opposed to what it is being…
Details up front: SELECT · early satiety · 1 mg. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…
The case in front of me: SURMOUNT-4 · fatigue. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single…
The specifics, since they change the answer: oral semaglutide · SOUL. I would like the mechanism, because I want to be able to reason about the cases nobody has…
Stated plainly: early satiety · a GLP-1 receptor agonist · TRIUMPH-1. I would like help reading this properly rather than being told what conclusion to reach. I have…
Details up front: reflux · tirzepatide · SURMOUNT-3. This is presented as though it settles something, and I am not convinced it does. I have two documents that…
Details up front: PIONEER-4 · early satiety. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…
Setup, so nobody has to ask: SOUL · early satiety. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is…